The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Interim safety results from the all cases post-marketing study (PMS) of sunitinib in 1,027 Japanese patients with renal cell carcinoma (RCC) or gastrointestinal stromal tumor (GIST).
N. Agata
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
N. Ueno
Employment or Leadership Position - Pfizer
H. Houzawa
Employment or Leadership Position - Pfizer
E. Ueda
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Y. Komatsu
No relevant relationships to disclose
T. Nishida
No relevant relationships to disclose
S. Naito
No relevant relationships to disclose
H. Akaza
No relevant relationships to disclose